For example, we have earlier shown the impact of different antibodies targeting epidermal growth factor receptor (EGFR) gene on the outcome EGFR analysis across human tumor types.54 Moreover, PD-L1 expression is routinely tested by IHC in cancers that are being considered for immune checkpoint-inhibitor therapy. This evidence concerns the gene EGFR and cancer.